Christina Bartzavali
Overview
Explore the profile of Christina Bartzavali including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
19
Citations
219
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Spiliopoulou A, Giannopoulou I, Assimakopoulos S, Jelastopulu E, Bartzavali C, Marangos M, et al.
Trop Med Infect Dis
. 2023 Nov;
8(11).
PMID: 37999622
Multidrug-resistant infections have become a threat for public health worldwide. The aim of the present study was to follow-up resistance patterns of spp. bloodstream isolates in a Tertiary University Hospital...
2.
Assimakopoulos S, Karamouzos V, Eleftheriotis G, Lagadinou M, Bartzavali C, Kolonitsiou F, et al.
Pathogens
. 2023 Feb;
12(2).
PMID: 36839558
(AB) has evolved over the last decades as a major problem in carbapenem-resistant gram-negative nosocomial infections, associated with high mortality rates especially in the intensive care unit (ICU). Recent reports...
3.
Papadimitriou-Olivgeris M, Bartzavali C, Karachalias E, Spiliopoulou A, Tsiata E, Siakallis G, et al.
Antibiotics (Basel)
. 2022 Oct;
11(10).
PMID: 36290072
Background: Ceftazidime/avibactam (CZA) is a new option for the treatment of KPC-producing Klebsiella pneumoniae. The aim of this study was to determine resistance patterns and carbapenemase genes among K. pneumoniae...
4.
Papadimitriou-Olivgeris M, Kolonitsiou F, Kefala S, Spiliopoulou A, Aretha D, Bartzavali C, et al.
Braz J Infect Dis
. 2022 May;
26(2):102353.
PMID: 35500645
Background: Patients with severe Coronavirus Disease 2019 (COVID-19) are treated with corticosteroids. Aim: We aimed to evaluate the role of corticosteroid treatment in candidemia development during the COVID-19 pandemic. Methods:...
5.
Papadimitriou-Olivgeris M, Bartzavali C, Georgakopoulou A, Kolonitsiou F, Papamichail C, Spiliopoulou I, et al.
Antibiotics (Basel)
. 2021 Jan;
10(1).
PMID: 33467394
Background: The increased frequency of bacteraemias caused by pandrug-resistant
(PDR-Kp) has significant implications. The aim of the present study was to identify predictors associated with mortality of PDR-Kp bacteraemias. Methods:...
6.
Papadimitriou-Olivgeris M, Bartzavali C, Georgakopoulou A, Kolonitsiou F, Mplani V, Spiliopoulou I, et al.
Clin Microbiol Infect
. 2021 Jan;
27(6):915.e1-915.e3.
PMID: 33444757
Objectives: Our aim was to validate the INCREMENT-CPE score (ICS) in patients hospitalized in the intensive care unit (ICU) with bacteraemia due to carbapenemase-producing Klebsiella pneumoniae (CP-Kp). Methods: The study...
7.
Papadimitriou-Olivgeris M, Bartzavali C, Nikolopoulou A, Kolonitsiou F, Mplani V, Spiliopoulou I, et al.
Antibiotics (Basel)
. 2020 Nov;
9(11).
PMID: 33228012
Background: Tigecycline is a therapeutic option for carbapenemase-producing (CP-Kp). Our aim was to evaluate the impact of the tigecycline's minimum inhibitory concentration (MIC) in the outcome of patients with CP-Kp...
8.
Papadimitriou-Olivgeris M, Bartzavali C, Lambropoulou A, Solomou A, Tsiata E, Anastassiou E, et al.
J Antimicrob Chemother
. 2019 Apr;
74(7):2051-2054.
PMID: 31002313
Objectives: Our aim was to determine the epidemiology of bloodstream infections (BSIs) by carbapenemase-producing Klebsiella pneumoniae (CP-Kp) after the introduction of ceftazidime/avibactam in January 2018 among ICU patients. Patients And...
9.
Papadimitriou-Olivgeris M, Spiliopoulou A, Kolonitsiou F, Bartzavali C, Lambropoulou A, Xaplanteri P, et al.
Infection
. 2018 Sep;
47(2):209-216.
PMID: 30196355
Purpose: The aim of the present study was to analyze candidaemia's epidemiology (incidence, species distribution, and susceptibility rates) and antifungal consumption during a 9-year period. Methods: All candidaemias recorded at...
10.
Papadimitriou-Olivgeris M, Bartzavali C, Spyropoulou A, Lambropoulou A, Sioulas N, Vamvakopoulou S, et al.
Diagn Microbiol Infect Dis
. 2018 Aug;
92(3):235-240.
PMID: 30076041
A matched 1:2 case-control study was conducted among critically ill patients in order to identify the risk factors of colistin or tigecycline-resistant carbapenemase-producing Klebsiella pneumoniae (ColR-Kp, TigR-Kp) bacteraemia. MIC to...